Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Myeloma Knowledge Exchange 2019 (MyKE Myeloma) /
Put a stop sign to aggressive multiple myeloma

10th - 11th May 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.05.19
Views: 987

Dr Francesca Gay - Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy

Dr Francesca Gay speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the classification and detection of aggressive disease.

She describes the prognostic features of this disease such as cytogenetics, presence of extramedullary disease and disease presentation, along with other factors that are used to evaluate aggressiveness.

Dr Gay also discusses the definition of aggressive disease, along with the therapy options available for these patients - in which precision medicine could play a role.

In terms of the future, she believes an improved strategy is needed, that takes factors such as prognostic features and response rates into account.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation